Transcription factor c-Myb: novel prognostic factor in
osteosarcoma

J 2022

Transcription factor c-Myb: novel prognostic factor in osteosarcoma

ŘÍHOVÁ, Kamila, Monika DÚCKA, Iva STANICZKOVÁ ZAMBO, Ladislava VYMĚTALOVÁ, Martin ŠRÁMEK et. al.

Základní údaje

Originální název

Transcription factor c-Myb: novel prognostic factor in osteosarcoma

Autoři

ŘÍHOVÁ, Kamila (203 Česká republika, domácí), Monika DÚCKA (703 Slovensko, domácí), Iva STANICZKOVÁ ZAMBO (203 Česká republika, domácí), Ladislava VYMĚTALOVÁ (203 Česká republika, domácí), Martin ŠRÁMEK (203 Česká republika, domácí), Filip TRČKA (203 Česká republika, domácí), Jan VERNER (203 Česká republika, domácí), Stanislav DRÁPELA (203 Česká republika, domácí), Radek FEDR (203 Česká republika), Tereza SUCHÁNKOVÁ, Barbora PAVLATOVSKÁ (203 Česká republika, domácí), Eva ONDROUŠKOVÁ (203 Česká republika, domácí), Irena KUBELKOVÁ, Danica ZAPLETALOVÁ (703 Slovensko, domácí), Štěpán TUČEK, Peter MÚDRY (203 Česká republika, domácí), Dagmar ADÁMKOVÁ KRÁKOROVÁ, Lucia KNOPFOVÁ (203 Česká republika, domácí), Jan ŠMARDA (203 Česká republika, domácí), Karel SOUČEK (203 Česká republika, domácí), Lubor BORSIG a Petr BENEŠ (203 Česká republika, garant, domácí)

Vydání

Clinical & Experimental Metastasis, Springer, 2022, 0262-0898

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.000

Kód RIV

RIV/00216224:14310/22:00125156

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1007/s10585-021-10145-4

UT WoS

000740192800001

Klíčová slova anglicky

c-Myb; Chemoresistance; Metastasis; Osteosarcoma; Prognosis; Proliferation

Štítky

14110112, 14110212, 14110321, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 5. 2022 10:05, Mgr. Marie Šípková, DiS.

Anotace

V originále

The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and adenoid cystic carcinoma. Recent studies revealed its expression also in osteosarcoma cell lines and suggested its functional importance during bone development. However, the relevance of c-Myb in control of osteosarcoma progression remains unknown. A retrospective clinical study was carried out to assess a relationship between c-Myb expression in archival osteosarcoma tissues and prognosis in a cohort of high-grade osteosarcoma patients. In addition, MYB was depleted in metastatic osteosarcoma cell lines SAOS-2 LM5 and 143B and their growth, chemosensitivity, migration and metastatic activity were determined. Immunohistochemical analysis revealed that high c-Myb expression was significantly associated with poor overall survival in the cohort and metastatic progression in young patients. Increased level of c-Myb was detected in metastatic osteosarcoma cell lines and its depletion suppressed their growth, colony-forming capacity, migration and chemoresistance in vitro in a cell line-dependent manner. MYB knock-out resulted in reduced metastatic activity of both SAOS-2 LM5 and 143B cell lines in immunodeficient mice. Transcriptomic analysis revealed the c-Myb-driven functional programs enriched for genes involved in the regulation of cell growth, stress response, cell adhesion and cell differentiation/morphogenesis. Wnt signaling pathway was identified as c-Myb target in osteosarcoma cells. Taken together, we identified c-Myb as a negative prognostic factor in osteosarcoma and showed its involvement in the regulation of osteosarcoma cell growth, chemosensitivity, migration and metastatic activity.

Návaznosti

NV18-07-00073, projekt VaV

Název: c-Myb a jeho transkripční program ve fyziologických a patologických osteogenních procesech

Investor: Ministerstvo zdravotnictví ČR, c-Myb a jeho transkripční program ve fyziologických a patologických osteogenních procesech

Citovat

ŘÍHOVÁ, Kamila, Monika DÚCKA, Iva STANICZKOVÁ ZAMBO, Ladislava VYMĚTALOVÁ, Martin ŠRÁMEK, Filip TRČKA, Jan VERNER, Stanislav DRÁPELA, Radek FEDR, Tereza SUCHÁNKOVÁ, Barbora PAVLATOVSKÁ, Eva ONDROUŠKOVÁ, Irena KUBELKOVÁ, Danica ZAPLETALOVÁ, Štěpán TUČEK, Peter MÚDRY, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Lucia KNOPFOVÁ, Jan ŠMARDA, Karel SOUČEK, Lubor BORSIG a Petr BENEŠ. Transcription factor c-Myb: novel prognostic factor in osteosarcoma. Clinical & Experimental Metastasis. Springer, 2022, roč. 39, č. 2, s. 375-390. ISSN 0262-0898. Dostupné z: https://dx.doi.org/10.1007/s10585-021-10145-4.

@article{1819457,
   author = {Říhová, Kamila and Dúcka, Monika and Staniczková Zambo, Iva and Vymětalová, Ladislava and Šrámek, Martin and Trčka, Filip and Verner, Jan and Drápela, Stanislav and Fedr, Radek and Suchánková, Tereza and Pavlatovská, Barbora and Ondroušková, Eva and Kubelková, Irena and Zapletalová, Danica and Tuček, Štěpán and Múdry, Peter and Adámková Krákorová, Dagmar and Knopfová, Lucia and Šmarda, Jan and Souček, Karel and Borsig, Lubor and Beneš, Petr},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s10585-021-10145-4},
   keywords = {c-Myb; Chemoresistance; Metastasis; Osteosarcoma; Prognosis; Proliferation},
   language = {eng},
   issn = {0262-0898},
   journal = {Clinical & Experimental Metastasis},
   title = {Transcription factor c-Myb: novel prognostic factor in osteosarcoma},
   url = {https://link.springer.com/article/10.1007%2Fs10585-021-10145-4},
   volume = {39},
   year = {2022}
}

TY  - JOUR
ID  - 1819457
AU  - Říhová, Kamila - Dúcka, Monika - Staniczková Zambo, Iva - Vymětalová, Ladislava - Šrámek, Martin - Trčka, Filip - Verner, Jan - Drápela, Stanislav - Fedr, Radek - Suchánková, Tereza - Pavlatovská, Barbora - Ondroušková, Eva - Kubelková, Irena - Zapletalová, Danica - Tuček, Štěpán - Múdry, Peter - Adámková Krákorová, Dagmar - Knopfová, Lucia - Šmarda, Jan - Souček, Karel - Borsig, Lubor - Beneš, Petr
PY  - 2022
TI  - Transcription factor c-Myb: novel prognostic factor in osteosarcoma
JF  - Clinical & Experimental Metastasis
VL  - 39
IS  - 2
SP  - 375-390
EP  - 375-390
PB  - Springer
SN  - 02620898
KW  - c-Myb
KW  - Chemoresistance
KW  - Metastasis
KW  - Osteosarcoma
KW  - Prognosis
KW  - Proliferation
UR  - https://link.springer.com/article/10.1007%2Fs10585-021-10145-4
N2  - The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and adenoid cystic carcinoma. Recent studies revealed its expression also in osteosarcoma cell lines and suggested its functional importance during bone development. However, the relevance of c-Myb in control of osteosarcoma progression remains unknown. A retrospective clinical study was carried out to assess a relationship between c-Myb expression in archival osteosarcoma tissues and prognosis in a cohort of high-grade osteosarcoma patients. In addition, MYB was depleted in metastatic osteosarcoma cell lines SAOS-2 LM5 and 143B and their growth, chemosensitivity, migration and metastatic activity were determined. Immunohistochemical analysis revealed that high c-Myb expression was significantly associated with poor overall survival in the cohort and metastatic progression in young patients. Increased level of c-Myb was detected in metastatic osteosarcoma cell lines and its depletion suppressed their growth, colony-forming capacity, migration and chemoresistance in vitro in a cell line-dependent manner. MYB knock-out resulted in reduced metastatic activity of both SAOS-2 LM5 and 143B cell lines in immunodeficient mice. Transcriptomic analysis revealed the c-Myb-driven functional programs enriched for genes involved in the regulation of cell growth, stress response, cell adhesion and cell differentiation/morphogenesis. Wnt signaling pathway was identified as c-Myb target in osteosarcoma cells. Taken together, we identified c-Myb as a negative prognostic factor in osteosarcoma and showed its involvement in the regulation of osteosarcoma cell growth, chemosensitivity, migration and metastatic activity.
ER  -

ŘÍHOVÁ, Kamila, Monika DÚCKA, Iva STANICZKOVÁ ZAMBO, Ladislava VYMĚTALOVÁ, Martin ŠRÁMEK, Filip TRČKA, Jan VERNER, Stanislav DRÁPELA, Radek FEDR, Tereza SUCHÁNKOVÁ, Barbora PAVLATOVSKÁ, Eva ONDROUŠKOVÁ, Irena KUBELKOVÁ, Danica ZAPLETALOVÁ, Štěpán TUČEK, Peter MÚDRY, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Lucia KNOPFOVÁ, Jan ŠMARDA, Karel SOUČEK, Lubor BORSIG a Petr BENEŠ. Transcription factor c-Myb: novel prognostic factor in osteosarcoma. \textit{Clinical \&{} Experimental Metastasis}. Springer, 2022, roč.~39, č.~2, s.~375-390. ISSN~0262-0898. Dostupné z: https://dx.doi.org/10.1007/s10585-021-10145-4.

Podrobný výpis o publikaci